Appraising Medical Trial Experiences of Ovarian Cancer Patients

Power Life Sciences Inc. (Industry)
Overall Status
Not yet recruiting ID

Study Details

Study Description

Brief Summary

Historically, participation in clinical trials has been highly skewed towards specific demographic groups. However, research identifying which trial attributes impact participation, in either positive or negative ways, is limited. This study invites participants to record a wide range of data on their clinical trial experience, with the goal being to identify factors which persistently limit patients' ability to participate in, or complete, a trial in which they were initially interested. Data will be analyzed through a range of demographic lenses, in hopes of discovering patterns which might improve the experience of future ovarian cancer patients.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Time Perspective:
    Official Title:
    Analyzing Factors of Patient Involvement in Ovarian Cancer Clinical Trials
    Anticipated Study Start Date :
    Apr 1, 2024
    Anticipated Primary Completion Date :
    Apr 1, 2025
    Anticipated Study Completion Date :
    Apr 1, 2026

    Outcome Measures

    Primary Outcome Measures

    1. Patient decides to enroll in clinical trial [3 Months]

    2. Patient remains in clinical trial to completion [12 months]

    Eligibility Criteria


    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    • Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed

    • Patient has been diagnosed with ovarian cancer

    • Subjects willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examination.

    Exclusion Criteria:
    • Inability to perform regular electronic reporting

    • Patient does not understand, sign, and return consent form

    • Pregnant, breastfeeding or expecting to conceive within the projected duration of the study

    Contacts and Locations


    No locations specified.

    Sponsors and Collaborators

    • Power Life Sciences Inc.


    • Study Director: Michael B Gill, Power Life Sciences Inc.

    Study Documents (Full-Text)

    More Information


    Responsible Party:
    Power Life Sciences Inc. Identifier:
    Other Study ID Numbers:
    • 89480700
    First Posted:
    Apr 6, 2023
    Last Update Posted:
    Apr 6, 2023
    Last Verified:
    Mar 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Plan to Share IPD:
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Keywords provided by Power Life Sciences Inc.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 6, 2023